Author name: rhoworldcom

Presentation

Navigating Complexities: Integrating Data from Ongoing Studies in Regulatory Submissions

Integrating data for regulatory submissions requires organizing and consolidating information from multiple studies for a project. The activities could include aligning variables from studies using different versions of CDISC standards and/or creating new variables to support integrated analyses. BUT, what happens when another layer of complexity is added? What if an ISS or ISE will include data from ongoing studies? What are key considerations when dealing with ongoing data?

Blog

Implementation of ICH M12 Guidance in 2024: What’s New for Drug Interactions?

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) adopted a harmonized drug-drug interaction (DDI) guidance (ICH M12) in May 2024. The next step is for this guidance to be implemented by ICH members; the FDA and EMA have already implemented the guidance. Read our blog for key highlights of the 2024 ICH M12 Guidance.

Blog

FMQs vs SMQs 

Sponsors often rely on Standardized MedDRA Queries (SMQs) to group adverse events for detection of safety signals across clinical trials. Additionally, the FDA has introduced their own version of adverse event groupings – FDA MedDRA Queries (FMQs). So, what’s the difference? 

Blog

Statistical Challenges with Site Enrollment in Clinical Trials 

Did you know that insufficient enrollment is the leading cause for clinical trials being halted? Study sponsors rightly embrace those sites which are high performing as they give a study the best opportunity to meet its enrollment targets. However, is it possible for there to be overreliance on these high enrolling sites? Unfortunately, the answer is yes. 

Scroll to Top